Sep 2018

Temple Therapeutics BV Announces Publication of Key Mechanism Data for Evitar™

  • By: Temple Therapeutics B.V.

Geleen, The Netherlands Temple Therapeutics BV (the “Company” or “Temple”)- September 10, 2018-Temple, a clinical stage biopharmaceutical company focused in developing therapeutics for fibrosis and oncology, announces the publication of groundbreaking mechanistic data for Evitar™ in Reproductive Sciences, a peer reviewed journal of the Society of Reproductive Investigations. Post-surgical adhesions are broadly recognized as the single greatest cause of surgical complications. Moreover, they have evaded effective intervention, until now.


Add a Comment

MeEt Us

View our upcoming events

View All Events